Literature DB >> 2354400

Squamous cell carcinoma of the head and neck heterotransplanted to nude mice. Take rate in relation to patient survival.

U K Zätterström1, J Wennerberg, R Attewell, A Ask.   

Abstract

Biopsy specimens from 62 human single primary squamous cell carcinomas (SCC) of the head and neck were xenografted into nude mice. To evaluate the prognostic significance of successful heterotransplantation, the 62 cases were retrospectively examined for survival, adjusting for possible confounders by multivariate analysis. The recorded take rate in the first passage was 24%. Median survival in the take group was 25 months versus 74 months in the nontake group, which is not statistically significant in this material. However, the numerical difference in survival between the take groups is in accordance with the concept that human tumors accepted as xenografts on nude mice may constitute a selected group of malignancies. This has to be considered when using heterotransplanted human tumors for in vivo investigations of SCC of the head and neck.

Entities:  

Mesh:

Year:  1990        PMID: 2354400     DOI: 10.1002/1097-0142(19900701)66:1<145::aid-cncr2820660126>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Conversion of premalignant human cells to tumorigenic cells by methylmethane sulfonate and methylnitronitrosoguanidine.

Authors:  G E Milo; C F Shuler; G Stoner; J C Chen
Journal:  Cell Biol Toxicol       Date:  1992 Oct-Dec       Impact factor: 6.691

2.  Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.

Authors:  Shaohua Peng; Chad J Creighton; Yiqun Zhang; Banibrata Sen; Tuhina Mazumdar; Jeffery N Myers; Stephen Y Lai; Adrian Woolfson; Matthew V Lorenzi; Diana Bell; Michelle D Williams; Faye M Johnson
Journal:  J Transl Med       Date:  2013-08-27       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.